Abstract: Disclosed are T cell receptors (TCRs) specific for one or more neoantigens and T cells engineered to express said TCRs as well as methods of their use for treating cancer.

Abstract: Disclosed are methods for identifying neoantigens and methods of treating cancer using neoantigens identified by said methods. The disclosure herein provide for methods for identifying neoantigens that can be used as a target for the treatment of a cancer, immunize a subject against a cancer, stimulate/induce immune responses, and/or isolate T cells that are reactive to said neoantigens.

Abstract: The subject invention pertains to materials and methods for the classification of cancers as sensitive or resistant to treatments based on protein-protein interactions, treatment of cancer, identification of biomarkers, identification of protein-protein interaction modulators, and selection of cancer treatments.

Abstract: The subject invention pertains to materials and methods for the classification of cancers as sensitive or resistant to treatments based on protein-protein interactions, treatment of cancer, identification of biomarkers, identification of protein-protein interaction modulators, and selection of cancer treatments.

Abstract: The subject invention pertains to materials and methods for the classification of cancers as sensitive or resistant to treatments based on protein-protein interactions, treatment of cancer, identification of biomarkers, identification of protein-protein interaction modulators, and selection of cancer treatments.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, including a system for providing treatment suggestions. The system includes a data warehouse including patient data for a plurality of patients associated with one or more care facilities, and one or more processors including instructions for implementing an evidence-based clinical decision engine. The engine is operable to: identify patient cohorts defined by the data in the data warehouse including identifying relevant cohorts that include a population of patients who are similar, both by phenotype and genotype, to a candidate patient; evaluate the patient cohorts to identify a cohort that is a best match for the candidate patient based on historical treatment information for patients in each candidate patient cohort; select a cohort from the plurality of cohorts; and provide a treatment suggestion to the patient or a care provider based on the selection.

Abstract: The subject invention pertains to materials and methods for the classification of cancers as sensitive or resistant to treatments based on protein-protein interactions, treatment of cancer, identification of biomarkers, identification of protein-protein interaction modulators, and selection of cancer treatments.